Patent Grant in the United States

RNS Number : 8644W

Evgen Pharma PLC

14 February 2017

 

For immediate release

14 February 2017

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

 Patent Grant in the United States

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that the United States Patent and Trademark Office has granted a patent that significantly broadens and extends the Company's intellectual property around its lead product, SFX-01.

SFX-01 is a synthetic version of the naturally occurring compound sulforaphane, which has been stabilised in an alpha-cyclodextrin lattice.  The current patent protection is composition of matter and runs until 2028. This new patent, granted today under number US9,567,405 and entitled Method of Synthesizing Sulforaphane, covers the manufacturing process and runs until 2033.

The exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.  

Evgen Pharma is currently conducting two Phase II trials of SFX-01, one in advanced breast cancer and one in a type of stroke called subarachnoid haemorrhage.

Dr Stephen Franklin, CEO of Evgen Pharma, commented: "This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia".

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Cowles, Stephanie Watson		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes and Rob Rees (Corporate Broking)		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its registered office at the Liverpool Science Park and is a virtual tenant at the Biohub at Alderley Park, Cheshire, UK.   It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information please visit: www.evgen.com

For a recent analyst research note on Evgen Pharma, please visit:

http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf

 

END

 

 

MSCEADALFFNXEFF